Browse ARHGAP5

Summary
SymbolARHGAP5
NameRho GTPase activating protein 5
Aliases RhoGAP5; p190-B; p190BRhoGAP; GFI2; growth factor independent 2; p100 RasGAP-associated p105 protein; p105 R ......
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cell membrane Peripheral membrane protein Note=Also membrane-associated in a fibrillar pattern that colocalizes with the alpha5-beta1 integrin receptor (ITGA5/ITGB1) for fibronectin.
Domain PF01846 FF domain
PF00071 Ras family
PF00620 RhoGAP domain
PF16512 p190-A and -B Rho GAPs FF domain
Function

GTPase-activating protein for Rho family members (PubMed:8537347).

> Gene Ontology
 
Biological Process GO:0007265 Ras protein signal transduction
GO:0007266 Rho protein signal transduction
GO:0030879 mammary gland development
GO:0048732 gland development
GO:0051056 regulation of small GTPase mediated signal transduction
Molecular Function GO:0003924 GTPase activity
GO:0005096 GTPase activator activity
GO:0005525 GTP binding
GO:0008047 enzyme activator activity
GO:0019001 guanyl nucleotide binding
GO:0030695 GTPase regulator activity
GO:0032561 guanyl ribonucleotide binding
GO:0042169 SH2 domain binding
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04510 Focal adhesion
hsa04670 Leukocyte transendothelial migration
Reactome R-HSA-194840: Rho GTPase cycle
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
Summary
SymbolARHGAP5
NameRho GTPase activating protein 5
Aliases RhoGAP5; p190-B; p190BRhoGAP; GFI2; growth factor independent 2; p100 RasGAP-associated p105 protein; p105 R ......
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ARHGAP5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolARHGAP5
NameRho GTPase activating protein 5
Aliases RhoGAP5; p190-B; p190BRhoGAP; GFI2; growth factor independent 2; p100 RasGAP-associated p105 protein; p105 R ......
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ARHGAP5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 3 Resistant to T-cell proliferation
Summary
SymbolARHGAP5
NameRho GTPase activating protein 5
Aliases RhoGAP5; p190-B; p190BRhoGAP; GFI2; growth factor independent 2; p100 RasGAP-associated p105 protein; p105 R ......
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ARHGAP5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1470.657
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0820.963
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1970.876
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0750.856
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3340.9
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.250.94
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0550.901
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0680.973
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0130.995
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2730.808
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8430.573
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0560.523
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ARHGAP5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.67.4-4.80.565
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1614014.3-14.30.209
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolARHGAP5
NameRho GTPase activating protein 5
Aliases RhoGAP5; p190-B; p190BRhoGAP; GFI2; growth factor independent 2; p100 RasGAP-associated p105 protein; p105 R ......
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ARHGAP5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolARHGAP5
NameRho GTPase activating protein 5
Aliases RhoGAP5; p190-B; p190BRhoGAP; GFI2; growth factor independent 2; p100 RasGAP-associated p105 protein; p105 R ......
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ARHGAP5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ARHGAP5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolARHGAP5
NameRho GTPase activating protein 5
Aliases RhoGAP5; p190-B; p190BRhoGAP; GFI2; growth factor independent 2; p100 RasGAP-associated p105 protein; p105 R ......
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ARHGAP5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolARHGAP5
NameRho GTPase activating protein 5
Aliases RhoGAP5; p190-B; p190BRhoGAP; GFI2; growth factor independent 2; p100 RasGAP-associated p105 protein; p105 R ......
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ARHGAP5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolARHGAP5
NameRho GTPase activating protein 5
Aliases RhoGAP5; p190-B; p190BRhoGAP; GFI2; growth factor independent 2; p100 RasGAP-associated p105 protein; p105 R ......
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ARHGAP5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolARHGAP5
NameRho GTPase activating protein 5
Aliases RhoGAP5; p190-B; p190BRhoGAP; GFI2; growth factor independent 2; p100 RasGAP-associated p105 protein; p105 R ......
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ARHGAP5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.